Thermo Fisher Scientificの空売り状況は、投資家がThermo Fisher Scientificの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Thermo Fisher Scientific (NYSE:TMO) 株価情報, 空売り情報

THERMO FISHER SCIENTIFIC INC

Thermo Fisher Scientific

Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year end-2024 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (54%).

Thermo Fisher Scientific Inc Common Stock

Thermo Fisher Scientific Inc

TomTom NV

TOMOE ENGINEERING CO by Tomoe Engineering Co. Ltd.

Tomoe Engineering Co Ltd

Trimol Group Inc

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is currently navigating a rare and telling phase in its journey through the Adhishthana Cycle. The stock is in its 18th Phase, simultaneously on both the weekly and monthly charts, a unique alignment that brings a powerful cyclical signal. Yet, while this convergence might appear synchronistic, the behavior across these timeframes paints two vastly different narratives.
<h3 class="wp-block-heading">Where Are We in the Cycle?</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="675" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065705/TMO-Adhishthana-1.png" alt="" class="wp-image-13508" style="width:759px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065705/TMO-Adhishthana-1.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065705/TMO-Adhishthana-1-300x169.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065705/TMO-Adhishthana-1-1024x576.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065705/TMO-Adhishthana-1-768x432.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig.1 TMO Adhishthana Phases (Source: Adhishthana.com)</figcaption></figure>
TMO is now in the 18th and final phase of the Adhishthana Cycle across both weekly and monthly timeframes. This rare dual alignment signals a transitional moment for the stock, but not without turbulence.
<h3 class="wp-block-heading">TMO Weekly Chart Breakdown</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="469" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065755/TMO-Weekly-Adhishthana.png" alt="Fig. 2 TMO Weekly Chart with Adhishthana Phases (Source: Adhishthana.com)" class="wp-image-13509" style="width:847px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065755/TMO-Weekly-Adhishthana.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065755/TMO-Weekly-Adhishthana-300x117.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065755/TMO-Weekly-Adhishthana-1024x400.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28065755/TMO-Weekly-Adhishthana-768x300.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 2 TMO Weekly Chart with Adhishthana Phases (Source: Adhishthana.com)</figcaption></figure>
According to the Adhishthana Principles, our proprietary cyclical framework that combines quantitative signals with behavioral archetypes, the structure of Phases 14, 15, and 16, also called the Guna Triads, determines how Phase 18 unfolds.
On the weekly timeframe, TMO's Guna Triads (Phase 14-16) were dominated by Rajoguna and Tamoguna. These archetypes reflect indecision, volatility, and bearish sentiment. In such conditions, the stock typically fails to attain Nirvana, which represents the highest point across the 18-phase cycle.&nbsp;
This explains the consolidation and persistent weakness we have been seeing in TMO since it entered the 18th Phase. So far, it's down by 38%.
<h3 class="wp-block-heading">TMO Monthly Chart Outlook</h3>
<figure class="wp-block-image aligncenter size-full is-resized"><img loading="lazy" decoding="async" width="1200" height="709" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28070432/TMO-Monthly.png" alt="Fig. 3 TMO Monthly Chart with Adhishthana Phases (Source: Adhishthana.com)" class="wp-image-13510" style="width:738px;height:auto" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28070432/TMO-Monthly.png 1200w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28070432/TMO-Monthly-300x177.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28070432/TMO-Monthly-1024x605.png 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/28070432/TMO-Monthly-768x454.png 768w" sizes="(max-width: 1200px) 100vw, 1200px" /><figcaption class="wp-element-caption">Fig. 3 TMO Monthly Chart with Adhishthana Phases (Source: Adhishthana.com)</figcaption></figure>
In contrast, the monthly charts tell a different story.
Here, the Guna Triads (Phases 14–16) were characterized by Satoguna, the most constructive of the three. This suggests high potential for Nirvana on the monthly timeframe. However, if that's the case, then why is TMO falling?&nbsp;
<h3 class="wp-block-heading">So Why Is TMO Falling?</h3>
The current weakness is primarily driven by the weekly chart&#8217;s bearish 18th phase, which ends on November 30, 2025. Until then, the stock is expected to remain under pressure. Only after this date do the bullish signals on the monthly chart begin to take precedence according to the Adhishthana Principles. This decline also aligns with what&#8217;s known as the &#8216;Death Move&#8217;, a pattern where a stock often undergoes a significant correction after entering Phase 18, before eventually reaching Nirvana.
This rare phase conjunction between the weekly and monthly charts has created a temporal dislocation: near-term pain, long-term potential.
Our clients pursuing shorter timeframes have been deploying bearish spreads since the weekly 18th phase began. However, once the phase concludes in late 2025, the strategy shifts. We expect increased bullish exposure into the stock, as the setup for long-term value and Nirvana on the monthly chart becomes dominant.
<h3 class="wp-block-heading">Final Thoughts</h3>
TMO is experiencing a rare and telling moment within its Adhishthana Cycle. The near-term outlook remains challenged due to a bearish guna triad on the weekly charts, but this consolidation may prove to be a healthy precursor to long-term upside. The monthly Phase 18 doesn't conclude until July 31, 2030, meaning long-term upside remains very much on the table after near-term turbulence subsides. TMO makes a compelling candidate for patient investors looking to capitalize on deep-cycle insights, if they time it right.&nbsp;

Equities

Long Ideas

WIIM

Technicals

Opinion

Signals

Trading Ideas

Thermo Fisher Scientific Stock: Big Upside Potential After Sluggishness Through November?

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 10 years by 1.16% on an annualized basis producing an average annual return of 11.71%. Currently, Thermo Fisher Scientific has a market capitalization of $148.51 billion. 
Buying $1000 In TMO: If an investor had bought $1000 of TMO stock 10 years ago, it would be worth $3,005.27 today based on a price of $393.66 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748033110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

$1000 Invested In Thermo Fisher Scientific 10 Years Ago Would Be Worth This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CVS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$59.00</td>
<td>$69.2K</td>
<td>2.4K</td>
<td>4.6K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$71.00</td>
<td>$39.1K</td>
<td>2.2K</td>
<td>4.0K</td>
</tr>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$200.00</td>
<td>$102.9K</td>
<td>4.0K</td>
<td>920</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$280.00</td>
<td>$99.0K</td>
<td>1</td>
<td>650</td>
</tr>
<tr>
<td>RXRX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$7.00</td>
<td>$32.5K</td>
<td>3.5K</td>
<td>279</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$65.00</td>
<td>$38.1K</td>
<td>6.6K</td>
<td>264</td>
</tr>
<tr>
<td>DHR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$190.00</td>
<td>$66.9K</td>
<td>25</td>
<td>42</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>05/30/25</td>
<td>$36.00</td>
<td>$27.4K</td>
<td>266</td>
<td>38</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• For CVS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), we notice a put option sweep that happens to be bearish, expiring in 7 day(s) on May 30, 2025. This event was a transfer of 752 contract(s) at a $59.00 strike. This particular put needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $69.2K, with a price of $92.0 per contract. There were 2468 open contracts at this strike prior to today, and today 4643 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 1000 contract(s) at a $71.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $39.1K, with a price of $39.0 per contract. There were 2294 open contracts at this strike prior to today, and today 4086 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a put option sweep with bullish sentiment. It expires in 238 day(s) on January 16, 2026. Parties traded 96 contract(s) at a $200.00 strike. This particular put needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $102.9K, with a price of $1075.0 per contract. There were 4074 open contracts at this strike prior to today, and today 920 contract(s) were bought and sold. 
• For TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we notice a put option sweep that happens to be bullish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 150 contract(s) at a $280.00 strike. This particular put needed to be split into 34 different trades to become filled. The total cost received by the writing party (or parties) was $99.0K, with a price of $660.0 per contract. There were 1 open contracts at this strike prior to today, and today 650 contract(s) were bought and sold. 
• Regarding RXRX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>), we observe a call option trade with bearish sentiment. It expires in 602 day(s) on January 15, 2027. Parties traded 250 contract(s) at a $7.00 strike. The total cost received by the writing party (or parties) was $32.5K, with a price of $130.0 per contract. There were 3518 open contracts at this strike prior to today, and today 279 contract(s) were bought and sold. 
• Regarding TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we observe a call option sweep with bearish sentiment. It expires in 56 day(s) on July 18, 2025. Parties traded 53 contract(s) at a $65.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $38.1K, with a price of $720.0 per contract. There were 6682 open contracts at this strike prior to today, and today 264 contract(s) were bought and sold. 
• For DHR (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>), we notice a put option sweep that happens to be bearish, expiring in 210 day(s) on December 19, 2025. This event was a transfer of 34 contract(s) at a $190.00 strike. This particular put needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $66.9K, with a price of $1970.0 per contract. There were 25 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 7 day(s) on May 30, 2025. Parties traded 15 contract(s) at a $36.00 strike. The total cost received by the writing party (or parties) was $27.4K, with a price of $1830.0 per contract. There were 266 open contracts at this strike prior to today, and today 38 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

Hims & Hers Health, Inc. Class A Common Stock

HIMS

RXRX

8 Health Care Stocks With Whale Alerts In Today's Session

Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co. in a <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45489983/regeneron-enters-into-asset-purchase-agreement-to-acquire-23andme-for-256-million-plans-to-maintai" rel="noreferrer noopener">$256 million deal</a> to boost its genetics-based drug discovery efforts.
The acquisition includes 23andMe&#8217;s Personal Genome Service, Total Health, Research Services divisions, its Biobank, and associated infrastructure. Regeneron plans to keep consumer services running without disruption and expects the transaction to close in the third quarter of 2025.
Regeneron pledged to uphold 23andMe&#8217;s privacy policies to address concerns over data use and comply with all applicable regulations. A court-appointed Customer Privacy Ombudsman will review the intended data use and oversee privacy safeguards throughout the process.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/44479516" rel="noreferrer noopener">23andMe&#8217;s Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers</a>
George D. Yancopoulos, Regeneron&#8217;s co-founder and chief scientific officer, emphasized the company&#8217;s long-term commitment to leveraging DNA in drug development.
He noted that Regeneron has already partnered globally to match de-identified genetic information from nearly three million participants with electronic health records, accelerating breakthroughs in treatments for cancer, infectious diseases, and immune disorders.
Aris Baras, head of the Regeneron Genetics Center, reaffirmed the company&#8217;s focus on ethical data use and scientific advancement. He said the acquisition supports Regeneron&#8217;s vision of utilizing large-scale genomic research to improve human health.
Following completion, 23andMe will become a wholly owned subsidiary of Regeneron. The transaction does not include the company&#8217;s Lemonaid Health division.
Regeneron held Cash and marketable securities of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45061738/regeneron-reports-first-quarter-2025-financial-and-operating-results" rel="noreferrer noopener">$17.625 billion</a> as of March 31, 2025.
Price Action: REGN shares traded lower by 0.66% to $590.40 at the last check Monday.
Photo by Michael Vi via Shutterstock

Biotech

Health Care

ARKG

IDNA

ILMN

REGN

Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal

In the current session, Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) is trading at $390.50, after a 3.83% drop. Over the past month, the stock fell by 8.66%, and in the past year, by 34.40%. With performance like this, long-term shareholders are more likely to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1747317624_0.png" alt="Past Year Chart" />

<h3>Evaluating Thermo Fisher Scientific P/E in Comparison to Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 44.19 in the Life Sciences Tools &amp; Services industry, Thermo Fisher Scientific Inc. has a lower P/E ratio of 23.82. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1747317624_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

P/E Ratio Insights for Thermo Fisher Scientific

General

CYBN

Cybin Engages Thermo Fisher To Support Phase 3 Supply And Potential Commercial Manufacturing Of CYB003 In Development For Major Depressive Disorder

Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) announced on Wednesday that it will invest at least $20 billion in the <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">U.S. through 2030</a>.
Research and development, plus U.S. manufacturing, will receive the bulk of the spending.
The company also expects higher job creation within the communities where Sanofi and its partners are located, which will help <a href="https://www.benzinga.com/pressreleases/25/05/n45414947/sanofi-to-invest-at-least-20-billion-in-the-us-through-2030-growing-investments-in-science-and-exp" target="_blank" rel="noreferrer noopener">enhance the U.S. supply chain</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a>
Sanofi has 13,000 US-based employees, according to CEO Paul Hudson.
&#8220;Our expected investments in the US will be substantial and will help ensure the production of key medicines in the U.S.,&#8221; he added.
Sanofi also expects to partner with other domestic manufacturers to help ensure the production of medicines in the U.S.  
Earlier in May, U.S. President&nbsp;Donald Trump's&nbsp;signed an executive order to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on&nbsp;<a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The White House wants facilities to come on board at a faster rate. It <a href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">estimates</a> that it can currently take five to 10 years to build new pharmaceutical manufacturing capacity, which it calls "unacceptable from a national-security standpoint.&#8221;
It&#8217;s not just Sanofi. <a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">Amid tariff uncertainty</a>, many drug companies are investing to boost production within the U.S.:
<ul class="wp-block-list">
<li>Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled&nbsp;<a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm&nbsp;Becton, Dickinson, and Company&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest&nbsp;$2.5 billion&nbsp;in U.S. manufacturing capacity&nbsp;<a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)  seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a $23 billion investment plan to expand in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>)&nbsp;announced that it will invest $50 billion in the U.S. over&nbsp;<a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Bristol-Myers Squibb &amp; Co.'s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)&nbsp;Christopher Boerner, chair and chief executive officer,&nbsp;<a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1VcoxvTN4f7-y-PqATDviEo" target="_blank" rel="noreferrer noopener">shared</a>&nbsp;plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Statnews.</li>
</ul>
Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) is one pharma company that did not highlight investments in new manufacturing plants. The company noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">products in the U.S</a>.
Price Action: Sanofi stock is down 1.53% at $49.20 at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45407486/novo-nordisk-inks-22-billion-deal-with-septerna-to-develop-oral-weight-loss-and-diabetes-drugs" target="_blank" rel="noreferrer noopener">Novo Nordisk Inks $2.2 Billion Deal With Septerna To Develop Oral Weight Loss And Diabetes Drugs</a></li>
</ul>
Image: Shutterstock

Large Cap

Movers

RHHBY

Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030

A report on May 13, 2025 shows that Senator Markwayne Mullin from Oklahoma sale stock in Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), valued between $290,010 and $700,000. According to the May filing, the transaction occurred on May 13, 2025.
At the time of writing, Thermo Fisher Scientific shares are trading down 3.05% at $415.87.
<h3>What Senator Has Been Trading Recently</h3>
In the past three years, Markwayne Mullin made 312 stock trades totaling more than $7.69 million. The largest trades involved stocks like Russell 1000 Ishares ETF and Invesco Actively Managed Exchange-Traded Fund Trus Invesco High Yield Select ETF. Their most notable trades made recently include key transactions: 
<ul>
<li>Materials ETF Vanguard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAW#NYSE">VAW</a>): $100,001 - $250,000 Sale</li>
<li>Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): $50,001 - $100,000 Sale</li>
<li>Valero Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLO#NYSE">VLO</a>): $50,001 - $100,000 Sale</li>
</ul>
Here's a summary of Markwayne Mullin's recent trades:
<table>
<thead>
<tr>
<th>Company</th>
<th>Ticker</th>
<th>Stock Type</th>
<th>Amount</th>
<th>Transaction Type</th>
<th>Transaction Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>ConocoPhillips</td>
<td>COP</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S</td>
<td>2025-04-08</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>TMO</td>
<td>STOCK</td>
<td>$50,001 - $100,000</td>
<td>S</td>
<td>2025-04-08</td>
</tr>
<tr>
<td>Texas Instruments</td>
<td>TXN</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S</td>
<td>2025-04-08</td>
</tr>
<tr>
<td>Valero Energy</td>
<td>VLO</td>
<td>STOCK</td>
<td>$50,001 - $100,000</td>
<td>S</td>
<td>2025-04-08</td>
</tr>
<tr>
<td>Zoetis</td>
<td>ZTS</td>
<td>STOCK</td>
<td>$15,001 - $50,000</td>
<td>S</td>
<td>2025-04-08</td>
</tr>
</tbody>
</table>
To keep an eye on Markwayne Mullin's trades and other government stock activity, check out our <a href="https://www.benzinga.com/gov-trades/members/markwayne-mullin">real-time tracking tool</a>!
<h3>The Importance of Congressional Transactions</h3>
A congressional transaction is when any representative or senator either buys or sells an individual stock.
Anyone working in Congress must file a Periodic Transaction Report to inform the public of their recent transaction within 30 days of being notified of the transaction and within 45 days of the transaction date.
In April 2012, Former President Barack Obama signed the STOCK Act into law. The act prohibits members of Congress from using private information given to them by their position for personal gain such as buying or selling a stock. The act also expanded disclosure requirements for members of Congress by requiring them to file a monthly disclosure.
<h3>Why Congressional Transactions Matter</h3>
Congressional transactions shouldn't be the primary reason for an investing decision, but they can be an important factor for an investor to consider.
When a senator or representative makes a new purchase, it could be an indication they expect the stock to rise.
A sale, on the other hand, can be made for a variety of reasons, and may not necessarily mean the seller thinks the stock will go down.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Government

Politics

This Senator Just Sold Up To $700K In Thermo Fisher Scientific Stock

Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) has outperformed the market over the past 20 years by 6.51% on an annualized basis producing an average annual return of 14.67%. Currently, Thermo Fisher Scientific has a market capitalization of $155.19 billion. 
Buying $100 In TMO: If an investor had bought $100 of TMO stock 20 years ago, it would be worth $1,584.63 today based on a price of $411.37 for TMO at the time of writing.
<h3>Thermo Fisher Scientific's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746716419_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Thermo Fisher Scientific Stock In The Last 20 Years

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Regulations

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

As May opens for business, shell-shocked stock market investors are waving goodbye to April with both hands. While the major stock indexes have <a href="https://www.benzinga.com/markets/25/04/45027002/benzinga-bulls-and-bears-netflix-novavax-intel-and-the-market-begins-to-bounce-back">bounced back</a> moderately over the last week, stocks fell 11% at one point and declined 20% since mid-February, primarily due to <a href="https://www.benzinga.com/trading-ideas/25/04/45050322/how-youll-know-the-tariff-troubles-are-over">tariff troubles</a> affecting the global economy.
That's not all. Consumer spending was at a two-year low in the first quarter of 2025, while first-quarter US gross domestic product fell by 0.3%, fueling talk of a recession on the horizon.
Older traders are talking about a &#8220;Templeton Moment&#8221; right now, and likely with good reason. The term stems from legendary trader John Templeton, who famously borrowed $10,000 to buy shares in every company trading on the New York Stock Exchange for under $1 during a market trough in 1939, during the Great Depression. The list included 104 companies, including 34 that were bankrupt. A few years later, Templeton banked huge gains on all but four stocks when he sold.
Today&#8217;s market could be your opportunity for something similar.
"It doesn&#8217;t resemble a &#8216;Templeton Moment,&#8217; but I would be cautious," said Eugenia Mykuliak, founder and executive director at B2PRIME Group, a global financial services provider for institutional investors. "Today&#8217;s market has more nuances, and we're not close to an &#8216;extreme&#8217; pessimism, unlike the 1930s. Even though there are some well-valued stocks out there, that's certainly not an invitation to buy in bulk."
Unlike the 1930's, which saw economic indicators drag across the board, this market has largely fallen victim to one malady.
&#8220;Uncertainty has been generated by the announcement, delay, magnitude, and duration of tariffs," said Karl Farmer, portfolio manager at Rockland Trust Bank. "With over 40% of the S&amp;P 500's revenues coming from outside the US, the tariffs can have some big impacts on inventory management and purchase plans as producers and consumers face higher prices."
Resulting market uncertainty means less confidence in profit consistency and usually lower multiples that investors place on earnings.
"Higher costs likely lead to lower profits if sellers cannot pass on the price increases to their customers, or at a minimum, it leads to lower consumption," Farmer said. "A lower multiple coupled with lower profits means lower market levels. The longer the tariffs remain, the more likely there will be behavior changes by both producers and consumers, as many will seek alternatives if they believe that higher prices are not temporary."
If the delayed reciprocal tariffs are implemented in full and there have been few negotiated breakthroughs, "then we have not seen the bottom," Farmer added.
Here are today&#8217;s buying opportunities and what to look out for.
<h2 class="wp-block-heading">Stocks To Pounce On At Lower Market Levels</h2>
Templeton or no Templeton, when the markets slide significantly, there's always low-hanging fruit available, and the US stock market is no different. Here are a few names that stock market gurus like in a shallower pricing market.
British American Tobacco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BTI#NYSE">BTI</a>). Sluggish stock markets spell opportunity for stocks that demonstrate good resilience amid uncertainty, especially those that turn to future-oriented technologies, Mykuliak said.
Shopify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NASDAQ">SHOP</a>). Mykuliak also likes stocks that offer investors a double dose of value.
"Shopify could be another good example of a perfect combination of AI and e-commerce, which are two powerful trends today," she said. "If merchants want to adapt to new retail realities, it&#8217;s a top choice for them."
Nike (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>). According to Farmer, defensive sectors such as consumer staples and utilities have held up very well this year. "Presently, we favor some names in other areas that may have been overly punished, but could provide above-average returns for the patient investor," he said.
Nike tops that list. Nike is no quick fix for a 2025 portfolio, but it makes sense in this market.
"A pop could be had here if tariffs end quickly," Farmer said. "Nike did have issues even before tariffs, but it's a reinvigorating brand, and it's repairing relationships. Plus, Nike shares are down 70% from peak to 2017 levels, which provides a decent entry point."
Air Products and Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>). Air Products is a market leader in industrial gas trading at a big discount to competitor Linde (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIN#NASDAQ">LIN</a>). "Future growth is coming from new projects and clean energy transition," Farmer said. "Additionally, the company has a strong and predictable recurring revenue model with on-site plants and 20-year contracts." Thermo Fisher Scientific (NYSE: TMO) is a market leader in life sciences, diagnostics and instruments.
"The stock is off 30% in the last three months on fears of spending cutbacks from customers who rely on federal funding for research," Farmer notes. "It's trading at less than market multiples for better earnings growth. Meanwhile, clarity on federal funding should mark a bottom."
<h2 class="wp-block-heading">More Than A "Buy the Dip" Scenario</h2>
As uncertainty prevails in the stock market, money managers are taking a more defensive stance with their portfolios, with one eye on historical trends.
"Historically, when volatility spikes—as it did in early April—the equity markets tend to see large gains one year later," said Andrew Constantinides, a financial advisor at Neil Jesani Wealth Management. "In the short term, however, calling the bottom is much harder. Investors should always remember: There can always be more downside in the market—unless it's at zero."
Constantinides said his firm is primarily focused on value and international stocks.
"Both categories have underperformed U.S. growth stocks over the past 10 years," he noted. "But Q1 of 2025 showed the first real signs of a cycle shift back toward value and international leadership. We favor developed markets, such as Europe and Asia. Our current sector focus is energy and financials—companies with low price-to-earnings ratios and high earnings yield. We have almost no exposure to large-cap tech."
<h2 class="wp-block-heading">5 Dark Horse Stocks Most Investors Aren't Following (But Should)</h2>
Every Friday, five overlooked stocks land on our ‘Whisper Index.' Like Coinbase before it surged 245% higher. And the biotech breakthrough Insmed before it jumped 20% in a single month. Beat Wall Street to these next potential winners. Access the Whisper Index <a href="https://www.benzinga.com/premium/ideas/benzinga-edge/?el=ResearchDaily&amp;he={{email}}&amp;adt_ei={{email}}&amp;utm_adType=SponsorAd&amp;utm_ad=RD0505&amp;utm_campaign=commandcenter">HERE</a>.
Editorial content from our Expert contributors is intended to be information for the general public and not individualized investment advice. Editors/contributors are presenting their individual opinions and strategies, which are neither expressly nor impliedly approved or endorsed by Benzinga.
Photo: Shutterstock

SHOP

This Market Is The Buying Opportunity Of A Lifetime

Argus Research analyst David Toung maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $620 to $470.

Price Target

Analyst Ratings

Argus Research Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $470

Thermo Fisher Scientific's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) short percent of float has risen 20.95% since its last report. The company recently reported that it has 4.79 million shares sold short, which is 1.27% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.52 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Thermo Fisher Scientific Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1745866842_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Thermo Fisher Scientific has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Thermo Fisher Scientific's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Thermo Fisher Scientific's peer group average for short interest as a percentage of float is 7.35%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Is Thermo Fisher Scientific Gaining or Losing Market Support?

With earnings season in full swing, let&#8217;s examine the performance of some major healthcare, utility, and financial services companies in Dan Loeb&#8216;s Third Point LLC portfolio that <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">reported earnings last week</a>.
Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>): Loeb acquired a stake in the company, attaining 350,000 shares <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43945075/dan-loeb-adjusts-healthcare-holdings-danaher-stake-trimmed-as-thermo-fisher-gains-favor" rel="noreferrer noopener">in the fourth quarter 2024</a>.
<ul>
<li>On April 23, the company reported&nbsp;first-quarter&nbsp;2025 adjusted earnings per share of&nbsp;$5.15,&nbsp;<a href="https://www.benzinga.com/calendars/earnings" target="_blank" rel="noreferrer noopener">beating the street view of&nbsp;$5.10</a>.</li>
<li>Quarterly sales of&nbsp;$10.36 billion, almost flat year over year, outpaced the analyst <a href="https://www.benzinga.com//node/44956678" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$10.23 billion</a>.</li>
<li>Thermo Fisher Scientific lowered 2025 adjusted EPS&nbsp;outlook from&nbsp;$23.10-$23.50&nbsp;to&nbsp;$21.76-$22.84&nbsp;vs. the consensus of&nbsp;$23.25 and revised sales&nbsp;guidance&nbsp;from&nbsp;$43.5 billion-$44 billion&nbsp;to&nbsp;$43.3 billion-$44.2 billion&nbsp;vs. consensus of&nbsp;$43.84 billion.</li>
<li>The company expects U.S.-China tariffs to hurt sales in China for products made in the U.S. This will reduce revenue by&nbsp;$400 million&nbsp;in 2025. These tariffs will also raise the cost of parts and <a href="https://www.benzinga.com//node/44966173" target="_blank" rel="noreferrer noopener">subassemblies sourced from China</a>.</li>
<li>After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a&nbsp;$375 million&nbsp;hit compared to previous&nbsp;guidance.</li>
<li>Several analysts lowered the price <a href="https://www.benzinga.com/quote/TMO/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast following the results</a>.</li>
<li>On April 24, the company said&nbsp;that it would invest an additional&nbsp;$2 billion&nbsp;in the <a href="https://www.benzinga.com//node/44995428" target="_blank" rel="noreferrer noopener">U.S. over&nbsp;the next four years</a>.</li>
<li>Year to date, Thermo Fisher fell about 21.03%, both underperforming the&nbsp;iShares U.S. Healthcare ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYH#NYSE">IYH</a>), which declined about 2.36%&nbsp;over the same time frame.</li>
</ul>
Pacific Gas &amp; Electric Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PCG#NYSE">PCG</a>): The investor had cut the stake from 49.75 million shares in the&nbsp;third quarter&nbsp;of 2024 to 48.5 million in <a target="_blank" href="https://www.benzinga.com//node/44384767" rel="noreferrer noopener">the&nbsp;fourth quarter&nbsp;of 2024</a>.
<ul>
<li>On April 24, the company reported first-quarter adjusted EPS of 33&nbsp;cents, down from 37 cents in the prior-year quarter and missing the estimates of 35 cents. Sales&nbsp;of $5.98 billion came below the <a href="https://www.benzinga.com/pressreleases/25/04/n44973765/pg-e-corporation-reports-first-quarter-results-on-track-to-deliver-solid-2025-residential-electric" target="_blank" rel="noreferrer noopener">street view of&nbsp;$6.13 billion</a>.</li>
<li>The company reiterated 2025 guidance for adjusted EPS at $1.48-$1.52&nbsp;compared to consensus of $1.50.</li>
<li>The company showed confidence in its equity strength, which is &#8216;fully satisfied&#8217; to fund the five-year capital plan of&nbsp;$63 billion&nbsp;through 2028.</li>
<li>Guggenheim analyst Shahriar Pourreza maintained a Neutral and raised the price forecast from&nbsp;$16&nbsp;to&nbsp;$17. Evercore ISI Group analyst Michael Lonegan retained an In-Line rating and boosted the <a href="https://www.benzinga.com/quote/pcg/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$15&nbsp;to&nbsp;$17</a>.</li>
<li>The company&#8217;s shares dipped around&nbsp;15.88%&nbsp;so far in 2025 compared to&nbsp;VanEck Uranium and Nuclear ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NLR#NYSE">NLR</a>) decline of 11.27%.</li>
</ul>
Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>): Loeb had acquired 640,000 shares in the company<a target="_blank" href="https://www.benzinga.com/25/04/44698171/trumps-tariff-push-sends-financials-lower-loebs-portfolio-take-a-hit" rel="noreferrer noopener"> in the fourth quarter of 2024</a>.
<ul>
<li>On April 23, the company reported first-quarter EPS of&nbsp;$4.25, which beat the analyst consensus estimate of&nbsp;$3.39&nbsp;by&nbsp;25.37%. Revenue of $4.25 billion, exceeded the analyst<a href="https://www.benzinga.com//node/44967199" target="_blank" rel="noreferrer noopener"> consensus estimate of&nbsp;$4.22 billion</a>.</li>
<li>Provision for credit losses of&nbsp;$1.2 billion&nbsp;decreased&nbsp;$253 million&nbsp;from the prior year quarter, driven by a&nbsp;$190 million&nbsp;favorable reserve change and a&nbsp;$97 million&nbsp;decrease in net charge-offs.</li>
<li>The company confirmed that it expects the merger with&nbsp;Capital One Financial Corp.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COF#NYSE">COF</a>) to close on or about May 18, 2025.</li>
<li>TD Securities analyst Moshe Orenbuch maintained a Buy rating and slashed the price forecast from&nbsp;$188&nbsp;to&nbsp;$184, while Truist Securities analyst Brian Foran boosted the <a href="https://www.benzinga.com/quote/dfs/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecast from&nbsp;$219&nbsp;to&nbsp;$229</a>.</li>
<li>The stock rose 4.98% compared to iShares Focused Value Factor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOVL#NYSE">FOVL</a>) decline of 5.67% YTD.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44911125/dan-loebs-bet-on-taiwan-semiconductor-looks-strong-as-q1-results-top-expectations" target="_blank" rel="noreferrer noopener">Dan Loeb&#8217;s Bet On Taiwan Semiconductor Looks Strong As Q1 Results Top Expectations</a></li>
</ul>
Image: Shutterstock

FOVL

iShares Trust Dow Jones US Healthcare Sector Index Fund

Tariffs Bite Dan Loeb's Portfolio: Thermo Fisher Hit Hard, Discover Shines

Scotiabank analyst Sung Ji Nam maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform and lowers the price target from $650 to $605.

Scotiabank Maintains Sector Perform on Thermo Fisher Scientific, Lowers Price Target to $605

Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced Thursday that it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">the next four years</a>.
As one of the largest manufacturers of medicines in the world, Thermo Fisher enables biopharma companies to develop and produce their <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44976531/thermo-fisher-scientific-invests-to-enhance-u-s-innovation-and-support-customers-manufacturing" rel="noreferrer noopener">medicines in America</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966205/analyst-sees-opportunity-in-danaher-stock-as-sentiment-improves" rel="noreferrer noopener">Analyst Sees Opportunity In Danaher Stock As Sentiment Improves</a>
These additional investments to the company&#8217;s American manufacturing capacity support a resilient U.S. healthcare supply chain and will have a strong multiplier effect across the American economy.
The $2 billion investment over the next four years includes:
<ul>
<li>$1.5 billion in capital expenditures to enhance and expand U.S. manufacturing operations</li>
<li>Complemented by $500 million in R&amp;D focused on high-impact innovation</li>
</ul>
Thermo Fisher CEO Marc N. Casper explained that by expanding in the U.S., the company ensures that &#8220;life-saving medicines and therapies will continue to be developed and produced in America for decades to come.&#8221;
This investment builds on Thermo Fisher&#8217;s 64 U.S. manufacturing operations in 37 states.
The company also invests $1 billion annually in R&amp;D in the U.S.
Over the next four years, the company will continue to expand its impact in the U.S. by creating high-paying jobs, adding manufacturing and lab services capacity, and investing in research and development.
On Wednesday, Thermo Fisher said that it expects U.S.-China tariffs to hurt sales in China for products made in the U.S. The company estimates this will reduce revenue by $400 million in 2025. These tariffs will also raise the cost of parts and subassemblies <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44966173/thermo-fisher-beats-q1-estimates-lowers-full-year-forecast-as-tariffs-and-costs-take-a-toll" rel="noreferrer noopener">sourced from China</a>.
After accounting for lower sales and higher costs—despite efforts to reduce the impact—the company expects adjusted operating income to take a $375 million hit compared to previous guidance.
Analyst Reactions on Thursday:
<ul>
<li>Baird maintains Thermo Fisher Scientific with an Outperform, lowering the price target from $603 to $573.</li>
<li>Wells Fargo maintains Thermo Fisher with an Overweight rating and lowers the price target from $580 to $570.</li>
<li>Evercore ISI maintains Thermo Fisher with an Outperform, lowering the price target from $585 to $500.</li>
<li>Stifel reaffirms the Buy rating for Thermo Fisher, lowering the price target from $665 to $620.</li>
</ul>
Price Action: TMO stock is down 2.57% at $420.55 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44981281/french-drugmaker-sanofi-clocks-20-q1-profit-growth-forecasts-strong-rebound-in-annual-profit" target="_blank" rel="noreferrer noopener">French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit</a></li>
</ul>
Image: Shutterstock

Thermo Fisher Doubles Down On US Manufacturing In $2B Expansion Plan

RBC Capital analyst Conor McNamara maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Outperform and lowers the price target from $651 to $637.

RBC Capital Maintains Outperform on Thermo Fisher Scientific, Lowers Price Target to $637

Thermo Fisher Scientific shares are trading lower after multiple firms cut their respective price targets on the stock.

UBS analyst Dan Leonard maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $715 to $500.

UBS Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $500

Stifel analyst Daniel Arias maintains Thermo Fisher Scientific (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Buy and lowers the price target from $665 to $620.

Stifel Maintains Buy on Thermo Fisher Scientific, Lowers Price Target to $620

Press Releases

Thermo Fisher Scientific to Present at TD Cowen 45th Annual Health Care Conference on March 3, 2025

Thermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business

Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

Trian Comments on Solventum's Sale of its Purification & Filtration Business

Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis

Thermo Fisher Scientific to Hold Earnings Conference Call on Wednesday, April 23, 2025

Thermo Fisher Scientific Reports First Quarter 2025 Results

Thermo Fisher Scientific Invests to Enhance U.S. Innovation and Support Customers' Manufacturing

Thermo Fisher Scientific to Present at BofA Securities 2025 Health Care Conference on May 13

Thermo Fisher Scientific Declares Quarterly Dividend

SOLV

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solutions

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Evotec

Illumina

IQVIA Hldgs

Medpace Hldgs

Mettler-Toledo International, Inc. Common Stock

Mettler-Toledo Intl

Niagen Bioscience

Repligen

Revvity

Sotera Health

Stevanato Group

Bio-Techne

Tempus AI

10x Genomics

Waters

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Servs

Argus Research

Scotiabank

RBC Capital

Stifel

Screenshot 2025-04-15 at 7.03.21 PM

MYNZ

Mainz Biomed Narrows Its Losses, Grows Revenue For Full Year 2024

Screenshot 2024-12-19 at 7.13.05 PM

Quest Diagnostics (NYSE: DGX) And Mainz Biomed (NASDAQ: MYNZ) Team Up To Commercialize ColoAlert Early Cancer Detection Screening In The U.S.

Screenshot 2024-11-21 at 6.41.48 PM

Mainz Biomed Inks Major Deal To Develop A Next-Generation Cancer Test

Screenshot 2024-11-12 at 8.43.58 PM

Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening

Comments

Thermo Fisher Scientific

空売り

Thermo Fisher Scientific (NYSE:TMO) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル